Skip to content Skip to sidebar Skip to footer
Subscribe Now
Celltrion
News
Celltrion Launches Osenvelt and Stoboclo (Biosimilars, Xgeva and Prolia) in the US
Shots: Celltrion has launched Osenvelt & Stoboclo, biosimilar versions of Amgen’s Xgeva & Prolia (denosumab) in the US Stoboclo (60mg/mL) treats postmenopausal women & men with osteoporosis at high fracture risk, glucocorticoid-induced osteoporosis in both sexes, & increases bone mass in men on androgen deprivation therapy for nonmetastatic prostate cancer & women on adjuvant aromatase inhibitors…
July 8, 20250Comments
VIEWPOINTS
Patient Insights: Jerry Kelleher in an Illuminating Conversation with PharmaShots 
Shots:  Abbott’s AVEIR DR is the first in the world dual-chamber leadless pacemaker  Jerry Kelleher, a clinical trial participant in the AVEIR DR study, shares his transformative journey with PharmaShots  Explore Jerry’s miraculous recovery with AVEIR DR, which helped enhance his quality of life   Saurabh: Jerry, can you take us back to life and describe…
July 7, 20250Comments
News
KalVista Reports the US FDA’s Approval of Ekterly (Sebetralstat) for Treating Hereditary Angioedema
Shots: The US FDA has approved Ekterly (sebetralstat) to treat hereditary angioedema (HAE) pts (≥12yrs.), with US availability expected immediately Approval was based on P-III (KONFIDENT) study assessing Ekterly (300mg & 600mg) vs PBO in 136 HAE pts (≥12yrs.) across 20 countries & KONFIDENT-S OLE study KONFIDENT data was published in The NEJM, which showed…
July 7, 20250Comments
News
BioAtla Presents Preliminary P-I Trial Data of BA3182 in Patients with Treatment Refractory Metastatic Adenocarcinoma at ESMO 2025
Shots: BioAtla has shared ongoing P-I dose-escalation trial data on BA3182 for treatment-refractory metastatic adenocarcinoma at ESMO 2025 As of June 20, 2025, 39 pts received BA3182 (QW) in the range of 0.0026 to 0.6mg with either 0, 1, or 2 priming doses, 4–7 days before treatment; 17 received IV doses (0.0026–0.032mg) & 22 received SC doses…
July 7, 20250Comments
News
PulseSight Therapeutics Reports First Patient Dosing with PST-611 in P-I (PST-611-CT1) Trial for Dry AMD/Geographic Atrophy 
Shots: PulseSight Therapeutics has dosed first pts in the P-I (PST-611-CT1) trial to assess safety & tolerability of PST-611 in humans The P-I single ascending dose study will evaluate safety & determine maximum tolerated dose of PST-611 for P-IIa trial in 6–12 pts with dry age-related macular degeneration/geographic atrophy pts, with preliminary results expected in…
July 7, 20250Comments
Novartis
News
Novartis Reports Topline P-III (GCAptAIN) Trial Findings of Cosentyx (Secukinumab) for Giant Cell Arteritis
Shots: Novartis has reported topline P-III (GCAptAIN) trial results on Cosentyx to treat adults with newly diagnosed or relapsing giant cell arteritis (GCA) The P-III (GCAptAIN) trial assessed efficacy & safety of Cosentyx (300 or 150mg) vs PBO, both in combination with a glucocorticoid taper regimen, in GCA pts across 27 countries In the trial,…
July 7, 20250Comments
THOUGHTSPOT
Choose the Right Microplate Reader: Strategic Guide for Advanced Biologics Development
In the competitive and ever-evolving world of biologics and protein therapy, each decision can significantly influence the trajectory of your research outcomes. Among these critical choices, selecting the optimal microplate reader stands out. Far from being just another lab instrument, your choice here can dramatically shape the accuracy, efficiency, and scalability of your scientific discoveries.…
July 7, 20250Comments
News
Seegene Introduces STAgora Platform for Real-Time Infectious Disease Analysis
Shots: Seegene has launched the STAgora platform for infectious disease analysis, with a formal launch planned at ADLM 2025to seek business partnerships & highlight STAgora's integration with Cureca PCR system  STAgora, when integrated with Seegene’s syndromic quantitative PCR tech, provides advanced visibility into single & multi-pathogen infections to allow clinicians to make faster, more informed…
July 7, 20250Comments